TR201719926A2 - PHARMACEUTICAL COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE LITHIUM SALTS AND VITAMIN C - Google Patents
PHARMACEUTICAL COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE LITHIUM SALTS AND VITAMIN C Download PDFInfo
- Publication number
- TR201719926A2 TR201719926A2 TR2017/19926A TR201719926A TR201719926A2 TR 201719926 A2 TR201719926 A2 TR 201719926A2 TR 2017/19926 A TR2017/19926 A TR 2017/19926A TR 201719926 A TR201719926 A TR 201719926A TR 201719926 A2 TR201719926 A2 TR 201719926A2
- Authority
- TR
- Turkey
- Prior art keywords
- vitamin
- pharmaceutical compositions
- compositions containing
- pharmaceutically acceptable
- lithium salts
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229910003002 lithium salt Inorganic materials 0.000 title 1
- 159000000002 lithium salts Chemical class 0.000 title 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- 229930003268 Vitamin C Natural products 0.000 abstract 1
- 229910052744 lithium Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Buluş lityum ve C vitaminini tek doz içerisinde birlikte içeren farmasötik kompozisyonlar ve bu kompozisyonların psikiyatrik hastalıklardan özellikle bipolar bozuklukların tedavisinde kullanımı ile ilgilidir.The invention relates to pharmaceutical compositions containing lithium and vitamin C together in a single dose and the use of these compositions in the treatment of psychiatric diseases, especially bipolar disorders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/19926A TR201719926A2 (en) | 2017-12-08 | 2017-12-08 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE LITHIUM SALTS AND VITAMIN C |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/19926A TR201719926A2 (en) | 2017-12-08 | 2017-12-08 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE LITHIUM SALTS AND VITAMIN C |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201719926A2 true TR201719926A2 (en) | 2019-06-21 |
Family
ID=67952612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2017/19926A TR201719926A2 (en) | 2017-12-08 | 2017-12-08 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE LITHIUM SALTS AND VITAMIN C |
Country Status (1)
| Country | Link |
|---|---|
| TR (1) | TR201719926A2 (en) |
-
2017
- 2017-12-08 TR TR2017/19926A patent/TR201719926A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (en) | NEW METHODS. | |
| CY1125488T1 (en) | PYRIDINE DERIVATIVES AND THERAPEUTIC USES AS TRPC6 INHIBITORS | |
| MX2018013472A (en) | Combination treatment of ocular inflammatory disorders and diseases. | |
| CL2019002240A1 (en) | Therapeutic dendrimers. | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| MX378566B (en) | N-METHYL-D-ASPARTATE SPIRO-LACTAM RECEPTOR MODULATORS AND THEIR USES. | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| MX391392B (en) | 5-5 FUSED RINGS AS C5a INHIBITORS. | |
| PH12021550047A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
| JOP20210090A1 (en) | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | |
| MA39765A (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
| MX387731B (en) | ORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE. | |
| EA202091112A1 (en) | SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION | |
| ECSP16086247A (en) | (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| EA201691796A1 (en) | N-SUBSTITUTED ASYMMETRIC UREA AND THEIR APPLICATION IN MEDICINE | |
| MX2019005309A (en) | Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use. | |
| MX2018014129A (en) | Pharmaceutical composition comprising eteplirsen. | |
| UY35890A (en) | USE OF LAQUINIMOD TO DELAY THE PROGRESSION OF HUNTINGTON'S DISEASE | |
| CY1119522T1 (en) | (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| TR201717703A2 (en) | APIXABAN FORMULATIONS | |
| TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
| MX384394B (en) | COMPOUND FOR USE IN THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES. | |
| TR201713325A2 (en) | PRODUCTION METHOD FOR FORMULATIONS CONTAINING RIVAROXABAN |